NeuroOne to Report Fiscal Second Quarter 2026 Results on May 12

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on improving surgical care for neurological disorders, announced it will release financial results for its fiscal second quarter ended March 31, 2026, before market open on Tuesday, May 12, 2026. The company will host an investor conference call and webcast at 8:30 a.m. Eastern time that same day to discuss the results, provide a corporate update, and answer questions from telephone participants.

The earnings call will be accessible via a toll-free dial-in at 888-506-0062 (U.S.) or 973-528-0011 (international), using participant access code 224785. A live webcast will be available at the company's investor relations page. Participants are encouraged to join at least five minutes before the start of the call. A replay of the call will be available through May 26, 2026, by dialing 877-481-4010 (U.S.) or 919-882-2331 (international) with replay passcode 53948. The webcast replay will remain accessible through May 12, 2027.

This earnings announcement is significant as it will provide insights into NeuroOne's financial performance and operational progress. The company has been advancing its electrode technology platform, which includes four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System for brain, and OneRF® Trigeminal Nerve Ablation System. These products are designed to offer minimally invasive, high-definition precision for diagnostic and therapeutic procedures, potentially reducing hospitalizations and surgical procedures while lowering costs and improving patient outcomes.

NeuroOne is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. The upcoming call may provide updates on these initiatives and the company's strategic direction. Investors and industry observers will be keen to hear about revenue trends, regulatory developments, and market adoption of NeuroOne's technologies. The company's performance in the second quarter could signal growth trajectories in the competitive neurotechnology market.

For more information about NeuroOne and its products, visit the company's website at nmtc1.com. The press release detailing the earnings call was originally distributed via NewMediaWire.